DEF: CapsoVision Sets 2026 Annual Meeting Date, Seeks Director Re-election

CapsoVision, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to be conducted virtually, with key agenda items including the re-election of Class I directors and ratification of its independent auditor.

Summary

• CapsoVision, Inc. is holding its 2026 Annual Meeting of Stockholders on June 11, 2026, at 9:00 a.m. Pacific Daylight Time.
• The meeting will be conducted virtually via live audio webcast, accessible at www.virtualshareholdermeeting.com/CV2026.
• Stockholders of record as of April 13, 2026, are eligible to vote.
• The primary agenda items include the election (re-election) of three Class I directors for a term until the 2029 annual meeting and the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for the year ending December 31, 2026.
• The company encourages stockholders to vote by proxy via the internet, phone, or mail, even if they plan to attend the virtual meeting.
• Proxy materials, including the Proxy Statement and Annual Report on Form 10-K for the year ended December 31, 2025, are available online.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily due to its routine nature as a proxy statement for an annual meeting. While it details standard corporate governance procedures and upcoming elections, the inclusion of a recent private placement and the proactive approach to governance are noted.

Positives

• The virtual meeting format is expected to increase attendance, improve communications, and result in cost savings for both stockholders and the Company.
• The company has a majority of independent directors on its board, meeting Nasdaq listing requirements.
• The Audit Committee and Compensation Committee are comprised entirely of independent directors.
• The company has adopted a Code of Ethics and Business Conduct and Corporate Governance Guidelines to ensure strong governance practices.
• The company has a Clawback Policy in place, effective as of its initial public offering, to recoup incentive-based compensation in cases of accounting restatements.
• The company has a robust Insider Trading Policy prohibiting speculative transactions and ensuring compliance with insider trading laws.

Negatives

• Two Section 16(a) reports were filed late for the fiscal year ended December 31, 2025: one for Rebecca Petersen regarding stock options exercised and shares bought, and another for Chen Lung Tsai regarding common shares bought on the open market.
• The company is an emerging growth company and thus benefits from reduced public company reporting requirements, which may mean less disclosure in certain areas like executive compensation.

Risks

• The election of directors is a non-routine matter, meaning broker non-votes could occur if beneficial owners do not provide voting instructions to their brokers.
• The company's bylaws and corporate governance guidelines allow for flexibility in leadership structure, which could be subject to change.
• The Board of Directors acts in lieu of a Nominating and Governance Committee, with independent directors fulfilling these functions, which could be a risk if not managed effectively.
• The company has entered into a consulting agreement with Dr. Joanne Imperial, a director, for clinical consulting and industrial affiliation services, which could present potential conflicts of interest if not managed appropriately.

Future Outlook

The company is preparing for its 2026 Annual Meeting of Stockholders, where key decisions regarding board composition and auditor ratification will be made. Stockholder proposals for the 2027 annual meeting are due by December 29, 2026, for inclusion in proxy materials, with specific deadlines for direct nominations also outlined.

Management Comments

• Utilizing the latest technology and a virtual meeting format will allow stockholders to participate from any location and we expect will enable increased attendance, improved communications and cost savings for our stockholders and the Company compared to an in person meeting.
• Whether or not you attend the Annual Meeting online, it is important that your shares be represented and voted at the Annual Meeting. Therefore, I urge you to promptly vote and submit your proxy via the Internet, by phone, or by mail.
• The Board of Directors recommends that you vote FOR the election (re-election) of the following three nominees as Class I directors to hold office until our 2029 annual meeting of stockholders.
• The Board of Directors recommends a vote FOR to ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for the 2026 fiscal year.
• The Board has concluded that our leadership structure is appropriate at this time because it facilitates effective oversight and further strengthens the Boards independent leadership and commitment to sound governance.
• Management discusses strategic and operational risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the strategic risks facing us.

Industry Context

StockSavvy.ai notes that CapsoVision's decision to hold a virtual-only annual meeting aligns with a growing trend in corporate governance, particularly post-pandemic, aimed at enhancing accessibility and reducing costs. The focus on director re-election and auditor ratification is standard for annual meetings, but the specific nominees and auditor choice reflect the company's ongoing operational and financial oversight.

Comparison to Industry Standards

• The company's board composition, with a majority of independent directors, meets and often exceeds the standards set by major exchanges like Nasdaq.
• The presence of dedicated Audit and Compensation Committees, both composed of independent directors, is a hallmark of strong corporate governance, consistent with best practices observed in publicly traded companies.
• The company's adoption of a Clawback Policy and Insider Trading Policy aligns with regulatory requirements and industry best practices for public companies, particularly those that have recently undergone an IPO.
• The fees paid to Baker Tilly US, LLP for audit and related services in 2025 ($958,200) appear within a reasonable range for a company of CapsoVision's size and complexity, though direct peer comparisons would require more detailed financial data.

Corporate Governance

Related Party Transactions

• From January 1, 2022, through December 31, 2024, the company issued and sold Series H preferred stock to investors, including Eliyahou Harari and Ching-Hang Shen, who are beneficial owners of more than 5% of the company's capital stock.
• On May 27, 2025, the company entered into a promissory note with Ching-Hang Shen, a 5% or greater stockholder, for a $1,000,000 loan.
• On July 11, 2025, in connection with the repayment of the Investor Loan, the company issued 7,508 shares of common stock to Ching-Hang Shen.
• On March 16, 2026, the company entered into a Securities Purchase Agreement for a private placement to raise approximately $14 million. Two investors, Star One Global Capital Limited (wholly owned by Ching-Hang Shen) and Eliyahou Harari, are related persons and purchased shares in this placement.
• Star One Global Capital Limited purchased 2,047,921 shares for $10,000,000, and Eliyahou Harari purchased 517,759 shares for $2,000,000 in the March 16, 2026 private placement.
• The company entered into a consulting agreement with Joanne Imperial, M.D. on July 23, 2025, for clinical consulting and industrial affiliation services, for which she was paid $2,750 in 2025.

Stakeholder Impact

• Shareholders: The re-election of directors and ratification of the auditor are key decisions impacting corporate governance and oversight. The virtual meeting format aims to increase participation. The recent private placement may dilute existing shareholders' ownership.
• Employees: The company's Code of Conduct and Insider Trading Policy apply to employees. Executive compensation is structured to align with long-term growth and retention.
• Directors: Non-employee directors receive cash and RSU compensation, with additional retainers for committee chairs and members. They are subject to independence requirements and governance guidelines.
• Creditors: The company's financial health and ability to meet obligations are implicitly relevant, though not directly addressed in this proxy statement.

Next Steps

• Stockholders are urged to vote their proxies promptly via the internet, phone, or mail.
• The company will hold its 2026 Annual Meeting of Stockholders on June 11, 2026.
• Voting results will be announced via a Form 8-K filing within four business days after the Annual Meeting.
• Stockholder proposals for the 2027 Annual Meeting must be submitted by December 29, 2026, for inclusion in proxy materials.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain significant new financial performance data or strategic shifts that would warrant a change in investment recommendation. The re-election of directors and auditor ratification are standard procedures. While the recent private placement is noted, its impact on valuation requires further analysis beyond this document.

Keywords

CapsoVision, Annual Meeting, Proxy Statement, Director Election, Independent Auditor, Baker Tilly, Corporate Governance, Stockholder Meeting, Virtual Meeting, SEC Filing